Journal
CANCER LETTERS
Volume 373, Issue 2, Pages 234-240Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.01.028
Keywords
Hepatocellular carcinoma; Circulating miRNAs; Biomarker; Prediction; Prevention
Categories
Funding
- State Key Project for Liver Cancer [2012ZX10002-009]
- National Research Program of China [2012CB316503, 2012AA02A201]
- National Natural Science Foundation of China [81221061, 81422032, 81272212, 81300306, 81372674]
- Natural Science Foundation of Shanghai [134119a3700, 20154Y0054]
Ask authors/readers for more resources
The extremely poor prognosis of patients with symptomatic hepatocellular carcinoma (HCC) diagnosed clinically at advanced stages suggests an urgent need for biomarkers that can be used for prospective surveillance and pre-clinical screening for early presence of pre-malignant lesions and tumors. In a retrospective longitudinal phase 3 biomarker study in seven medical centers of China, time-series and 6 months interval-serum samples were collected from chronic hepatitis B virus infected (CHB) patient cohorts at the pre-malignant or pre-clinical stages (average 6 months prior to clinical diagnosis) and CHB patients that did not develop cancer, and circulating miRNAs measured. A set of serum miRNAs including miR-193a-3p, miR-369-5p, miR-672, miR-429 and let-7i* were identified in pre-clinical HCC patients and have the potential to screen for CHB patients at high risk to develop HCC 6-12 months after miRNAs measurement. These circulating miRNAs combined with the conventional screening tools using alpha-fetoprotein and ultrasound, may have great promise for the prediction and prevention of HCC in high-risk populations. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available